Finding. If GATOR1 cannot restrain mTORC1, you can still take the scaffold away. Hadj-Aissa, Dutchak and colleagues fire antisense oligonucleotides at RAPTOR. RAPTOR protein falls in mouse and human systems, and pathological mTORC1 signalling falls in GATOR1-deficient models. Neurons stop being so hyperexcitable. Astrocyte mitochondria, which this disease remodels, recover as stated. Spontaneous seizures drop. One treatment lengthens life in both neuronal and astrocytic GATOR1-deficiency models.
Why this paper matters
NPRL2, NPRL3 and DEPDC5 are among the commonest genetic epilepsies. Rapalogs are blunt. An ASO against RAPTOR is a way to turn the volume down on mTORC1 without inventing a new kinase inhibitor. The mitochondrial reason to file it is the astrocyte: metabolic remodeling of glial mitochondria is on the rescue list, not a footnote.
What they actually measured
ASO, RAPTOR, mTORC1, excitability, astrocyte mitochondria, seizures, survival. Single-dose longevity is the standout in vivo claim.
How to read the score
High 80s. Genetic epilepsy, ASO, seizures, survival, glial mitochondria. Confidence is high for the mouse package.
Caveats
No human dosing. Mitochondrial rescue needs a number in the figures. Over-suppressing RAPTOR is a theoretical toxicity.
What to do with it
If you model GATOR1 astrocytes, add a mitochondrial assay to the ASO readout. If you develop CNS ASOs, this is a RAPTOR sequence to watch. Do not stop anti-seizure medicine from this brief.